IDStewardship

JUNE 6, 2023

In this article, ChatGPT provides witty insights into the cross-roads of artificial intelligence and infectious diseases. Interview with: ChatGPT by OpenAI Interview by: Timothy P. Gauthier, Pharm.D., BCPS, BCIDP Article Posted 7 June 2023 With the exception of the questions in bold, this entire text was written by ChatGPT. The only thing removed from the questions is the instruction “in a witty way” and a character limit was used in each of the questions.

Immunization 201

Immunization 201

PhRMA

JUNE 7, 2023

The Inflation Reduction Act (IRA) makes significant changes to Part D’s benefit structure and coverage, which will require careful policy development and thoughtful implementation. On Monday, PhRMA submitted comments on the Calendar Year 2025 Part D Redesign changes, outlining key considerations for the Centers for Medicare and Medicaid Services (CMS) to help mitigate against potential disruptions to seniors’ access to medicines through Part D.

147

147

PhRMA

JUNE 2, 2023

With Congress discussing policy changes that would lower drug costs for patients and rein in powerful middlemen, insurers and their PBMs are dusting off their old playbook and once again threatening to increase costs for employers if required to do their job and actually provide meaningful coverage to patients. But recent remarks by one executive make clear that the PBM industry has a choice: protect its profits or lower costs for patients.

Insurance 225

Insurance 225

Drug Topics

JUNE 6, 2023

With the rise of prescription digital therapeutics, pharmacists will need to prepare to manage the new paradigms of care.

176

176

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

Pharmacy Times

JUNE 2, 2023

Investigators found thinner ventricular walls, disorganized and ruptured myocardial fiber, mild inflammatory infiltration, and mild epicardia or interstitial fibrosis in the hearts of mice infected with COVID-19.

162

162

STAT

JUNE 7, 2023

An unusually early and ferocious outbreak of forest fires across Canada has sent unprecedented amounts of smoke pollution to regions of the eastern United States unaccustomed to such hazards. Three years after the onset of the Covid-19 pandemic, the ensuing air pollution has once again put respiratory health at the forefront of many North Americans’ minds.

143

143

Drug Topics

JUNE 1, 2023

Years of steady price increases have made access to the essential medicine more difficult for millions of Americans with diabetes.

181

181

Pharmacy Times

JUNE 5, 2023

It’s imperative to redefine the future of pharmacy to help ensure a robust pipeline of future pharmacists and create a culture that helps ensure pharmacists live their purpose and passion.

Community Pharmacies 144

Community Pharmacies 144

STAT

JUNE 6, 2023

Is the pandemic over ? On the one hand, Covid-19 is clearly still with us. In the U.S., over the past month there was a weekly average of 557 deaths , though the numbers are dropping sharply, from 849 four weeks ago to 208 last week. On the other, for those who are not vulnerable or immune compromised, most facets of life have returned to normal, thanks to high levels of immunity from vaccines, boosters, and past infections.

Hospitals 143

Hospitals Immunization Vaccines 143

Fierce Pharma

JUNE 7, 2023

Merck has taken the lead, filing a lawsuit seeking to overturn drug pricing measures in the Inflation Reduction Act (IRA). | Merck has filed a lawsuit seeking to overturn drug-pricing measures in the Inflation Reduction Act (IRA). Now, emboldened by the New Jersey drugmaker, other biopharma CEOs are making their concerns known. At the BIO International Convention, Biogen CEO Chris Viehbacher registered severe criticism of the IRA and said his company was considering filing its own lawsuit.

130

130

Fierce Healthcare

JUNE 2, 2023

Pharma giant Bayer is launching a precision health unit as it ramps up its investment in consumer-facing digital health tools. | Pharma giant Bayer is launching a precision health unit as it ramps up its investment in consumer-facing digital health tools.

144

144

Drug Topics

JUNE 6, 2023

According to a spokesperson, the company is prepared to take the lawsuit to the Supreme Court.

180

180

Pharmacy Times

JUNE 6, 2023

Recent debates have surrounded whether cognitive deficits, specifically in middle-aged patients, may be driven by cardiovascular and metabolic comorbidities instead of distinct obstructive sleep apnea processes.

122

122

STAT

JUNE 6, 2023

For young life scientists hoping to land a prestigious faculty job in academia, postdoctoral research is practically a requirement. But it’s not a path equally open to everyone. Freshly minted life science Ph.D. graduates who have started families or have big loans, or are Black or female, say they plan to pursue postdoc positions at lower rates than their peers, according to a STAT analysis that includes previously unreported data from the National Center for Science and Engineering Stat

132

132

Fierce Pharma

JUNE 4, 2023

AstraZeneca and Daiichi Sankyo’s Enhertu has already made waves in breast cancer treatment. | AstraZeneca and Daiichi Sankyo’s Enhertu has already made waves in breast cancer treatment. Now, the companies are positioning the HER2 antibody-drug conjugate for expansion into other tumor types with data that researchers view as very compelling.

127

127

Fierce Healthcare

JUNE 6, 2023

Mayo Clinic is collaborating with Google Cloud to supercharge search tools with generative AI. | Mayo Clinic is collaborating with Google Cloud to supercharge search tools with generative AI. The health system aims to use the buzzy new technology to make it easier for doctors to get access to relevant medical notes, research papers or clinical guidelines.

Mayo Clinic 117

Mayo Clinic 117

Drug Topics

JUNE 6, 2023

A research article outlines the future of artificial intelligence in health care.

187

187

Pharmacy Times

JUNE 6, 2023

Findings highlight the potential efficacy of combining 2 novel bispecific therapies, teclistamab-cqyv and talquetamab, which target distinct antigens on myeloma cells.

122

122

STAT

JUNE 1, 2023

In a bold move, Coherus BioSciences plans to sell a biosimilar version of Humira — one of the world’s best-selling medicines — at a steep discount, and will work with Mark Cuban’s generic drug company to make the medicine available directly to consumers for even less. Specifically, the Coherus medicine will carry a $995 list price for a carton of two autoinjectors, an 85% discount from the $6,922 that AbbVie charges for Humira, which is used to treat rheumatoid arthri

Pharmaceutical Companies 145

Pharmaceutical Companies Pharmaceutical Companies 145

Fierce Pharma

JUNE 7, 2023

The rush to provide revolutionary weight-loss drugs to obese patients has reached the U.K. | The rush to provide revolutionary weight-loss drugs to obese patients has reached the U.K. On Wednesday, the government unveiled a two-year pilot program that will allow Novo Nordisk’s Wegovy to be given to more overweight participants, even though the treatment has yet to be launched there.

113

113

Fierce Healthcare

JUNE 1, 2023

The Centers for Medicare and Medicaid Services outlined plans Thursday to broadly cover a new class of Alzheimer’s drugs once the medications get full approval from the Food and Drug Administration | CMS outlined plans Thursday to broadly cover a new class of Alzheimer’s drugs once the medications get full approval from the Food and Drug Administration.

FDA 144

FDA 144

Drug Topics

JUNE 2, 2023

New research suggests that chronotropic incompetence contributes to exercise limitations in Long COVID.

187

187

Pharmacy Times

JUNE 1, 2023

Pfizer Inc’s bivalent respiratory syncytial virus (RSV) vaccine Abrysvo is indicated to prevent lower respiratory tract disease caused by RSV in individuals 60 years of age and older.

FDA 139

FDA Vaccines 139

STAT

JUNE 4, 2023

CHICAGO — An antibody that delivers chemotherapy directly to tumor cells extended the lives of women with a form of advanced ovarian cancer in a large study, researchers reported Sunday. The drug, called Elahere, is made by the biotech company Immunogen. It was granted conditional approval in the U.S. last November based on preliminary evidence showing it shrank tumors.

Chemotherapy 134

Chemotherapy 134

Fierce Pharma

JUNE 6, 2023

The pharma industry has voiced loud complaints about the Biden administration's Inflation Reduction Act, specifically focusing on a clause that will allow Medicare to negotiate the prices of top-se | The pharma industry has voiced loud complaints about the Biden administration's Inflation Reduction Act, specifically focusing on a clause that will allow Medicare to negotiate the prices of top-selling pharmaceuticals.

108

108

Fierce Healthcare

JUNE 5, 2023

The roughly half of American smartphone users with iPhones will notice new health and pri | Apple brings its Health app to the iPad while offering new vision and mental health features to its suite of devices.

119

119

Drug Topics

JUNE 1, 2023

A majority of patients say that taking cannabis helps them with chronic pain management and other conditions.

186

186

Pharmacy Times

JUNE 3, 2023

Fecal microbiota transplant from responders to non-responders was able to rescue immune checkpoint inhibition use in patients with melanoma, with 40% of patients showing clinical benefit.

Immunization 132

Immunization 132

STAT

JUNE 6, 2023

BOSTON — As Biogen’s new CEO Chris Viehbacher pores over Biogen’s books and scouts out M&A deals, he may have one advantage his predecessor didn’t: a good relationship with his board of directors. Investors have expressed hope over the last several years that Biogen would make more acquisition deals, but it’s been a point of contention within the company.

119

119

Fierce Pharma

JUNE 1, 2023

After a panel of independent experts endorsed a narrow approval for AstraZeneca and Merck’s Lynparza in metastatic castration-resistant prostate cancer (mCRPC), the FDA has followed suit. | The drug is now approved to treat BRCA-mutated metastatic castration-resistant prostate cancer in combination with Johnson & Johnson’s Zytiga and a corticosteroid.

FDA 127

FDA 127

Fierce Healthcare

JUNE 1, 2023

A pair of new healthcare workforce surveys outline widespread reports of discrimination, racism and workplace violence perpetuated by patients and coworkers alike. | A pair of polls released this week detail the interpersonal difficulties nurses and other healthcare workers face in the workplace.

133

133

Drug Topics

JUNE 7, 2023

Air quality in New York City was the worst in the world on Tuesday morning.

148

148

Pharmacy Times

JUNE 5, 2023

In data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, amivantamab-vmjw plus lazertinib demonstrated promise as a first-line treatment for patients with advanced EGFR-mutated non-small cell lung cancer.

123

123

STAT

JUNE 1, 2023

Tempus, a company that combines DNA sequencing for cancer with artificial intelligence, said Thursday that it is launching a voice-and-text assistant called Tempus One that will give physicians much easier access to patient data. The AI assistant is being launched ahead of the annual meeting of the American Society of Clinical Oncology in Chicago. Eric Lefkofsky, Tempus’ founder and CEO, told STAT Tempus will be rolling the product, called Tempus One, out to the 6,000 doctors that prescri

130

130

Pharmaceutical Technology

JUNE 6, 2023

Alkeus Pharmaceuticals has raised $150m in Series B financing to support the registration and launch of gildeuretinol (ALK-001) to treat Stargardt disease, a genetic cause of blindness in children and young adults. Led by Bain Capital Life Sciences, the financing round has also seen participation from Sofinnova Investments, TCGX and Wellington Management.

105

105

Fierce Healthcare

JUNE 1, 2023

Less than a month after CVS Health acquired Oak Street Health, the primary care provider plans to expand into four more states. | The company plans to open value-based primary care centers in Little Rock, Arkansas; Des Moines and Davenport, Iowa; Kansas City, Kansas and Richmond, Virginia, beginning this summer. Oak Street Health will operate centers in 25 states by the end of the year.

123

123